Wednesday, July 8, 2026

pharma · Atopic Dermatitis Eczema · Plaque Psoriasis · ARQT

Arcutis Biotherapeutics

Arcutis Biotherapeutics clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2945 Townsgate Rd, Westlake Village, California 91361, US HQ
2016 Founded
427 Employees
Public company Type
ARQT · NYSE Ticker
Company details
Status
Public
HQ
2945 Townsgate Rd, Westlake Village, California 91361, US
Founded
2016
Employees
427
Programs
27
Drugs
3
Patents
30
Intelligence · Clinical Programs

Arcutis Biotherapeutics projects

13 ClinicalTrials.gov programs sponsored by Arcutis Biotherapeutics.

Arcutis Biotherapeutics has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ARQ-151 cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial
  2. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    2 trials
  3. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    1 trial
  4. ARQ-154

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial
  5. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Chronic Hand Eczema

    phase 2 small molecule completed

    1 trial
  6. ARQ-252 cream 0.3%

    Arcutis Biotherapeutics

    Vitiligo

    phase 2 small molecule terminated

    1 trial
  7. Roflumilast

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial
  8. Roflumilast Cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial
  9. Roflumilast Cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial
  10. Roflumilast Foam 0.3%

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial
  11. Roflumilast foam 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial
  12. Roflumilast topical 0.3% foam

    Arcutis Biotherapeutics

    Non-segmental Vitiligo

    phase 2 small molecule active

    1 trial
  13. Topical roflumilast 0.3% foam

    Arcutis Biotherapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Arcutis Biotherapeutics have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.